Lv11
40 积分 2026-04-15 加入
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
4小时前
已完结
Predictive value of the hemoglobin–albumin–lymphocyte–platelet (HALP) index for ICU mortality in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
4小时前
已完结
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma
1个月前
已完结
MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab
1个月前
已完结
Benralizumab and mepolizumab treatment outcomes in two severe asthma clinics
2个月前
已关闭
Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years’ Therapy
2个月前
已完结
Head-to-Head Effectiveness Comparison of Biological Therapies in Patients With Mixed Eosinophilic and Allergic Severe Asthma
2个月前
已完结
皖公网安备34019202002308
